Chest
Clinical InvestigationsPLEURAL DISEASEPredicting Survival in Patients With Recurrent Symptomatic Malignant Pleural Effusions: An Assessment of the Prognostic Values of Physiologic, Morphologic, and Quality of Life Measures of Extent of Disease
Section snippets
Patients
All patients with recurrent symptomatic malignant pleural effusions referred to the Interventional Pulmonology service of University of California at San Diego Medical Center for thoracoscopic pleurodesis were eligible to participate in this study. The diagnosis of pleural carcinomatosis was established by positive pleural fluid cytology on thoracentesis or evidence of neoplasm on pleural biopsy prior to referral. Pleurodesis was performed by thoracoscopic insufflation of sterile, asbestos-free
Results
Between 1993 and June 1, 1998, 85 consecutive patients (42 men and 43 women), underwent pleurodesis by thoracoscopic talc insufflation for recurrent symptomatic malignant pleural effusions. Their mean age was 60 ± 14 years. A complete follow-up was obtained for 82 of the 85 patients (96%). All 85 patients had an assigned EPC score and KPS score, but the duration of survival could not be determined in 2 patients, both of whom were undocumented immigrants. These patients were thus assigned a
Discussion
This study was designed to systematically evaluate the potential prognostic value of specific physiologic, morphologic, and functional measures in patients with recurrent symptomatic malignant pleural effusions. The major outcome variable, duration of survival, was measured from the time of thoracoscopy to the date of death or study closure. Because all of the patients had recurrent, symptomatic malignant pleural effusions and subsequently underwent pleurodesis by thoracoscopic talc
References (20)
- et al.
Carcinomatous involvement of the pleura
Am J Med
(1977) - et al.
Survival time of patients with pleural metastatic carcinoma predicted by glucose and pH studies
Chest
(1989) - et al.
Survival and talc pleurodesis in metastatic pleural carcinoma, revisited: report of 125 cases
Chest
(1993) - et al.
Thoracoscopic talc poudrage in malignant pleural effusions: effective pleurodesis despite low pleural pH
Chest
(1998) - et al.
Carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA) and other prognostic indicators in squamous cell lung cancer
Lung Cancer
(1993) - et al.
The prognostic significance of tumor cell detection in intraoperative pleural lavage and lung tissue cultures for patients with lung cancer
J Thorac Cardiovasc Surg
(1997) - et al.
Prognostic significance of pleural lavage cytology immediately after thoracotomy in patients with lung cancer
J Thorac Cardiovasc Surg
(1993) - et al.
Pleural cytologies in lung cancer without pleural effusions
Ann Thorac Surg
(1997) - et al.
Pleural fluid pH in malignant effusions
Ann Intern Med
(1988) - et al.
Low glucose and pH levels in malignant pleural effusions: diagnostic significance and prognostic value in respect to pleurodesis
Am Rev Respir Dis
(1989)
Cited by (180)
Effect of chemotherapy, immunotherapy, and targeted therapies on removal of indwelling pleural catheters in non-small cell lung cancer patients with malignant pleural effusions
2023, Respiratory MedicineCitation Excerpt :The introduction of targeted therapies have prolonged survival in patients with adenocarcinoma and EGFR mutations who develop MPE to a median survival of 14–21 months depending on time of developing the MPE (at diagnosis or following disease progression, respectively) [9]. Survival tends to be longer in those with higher performance scores [10,11]. Recent advances in treatments for NSCLC, including targeted therapies and immunotherapies, have improved tumour response and survival compared to chemotherapy [12–17].
Update on the diagnosis and management of malignant pleural effusions
2022, Respiratory MedicineIntrapleural interleukin-2–expressing oncolytic virotherapy enhances acute antitumor effects and T-cell receptor diversity in malignant pleural disease
2022, Journal of Thoracic and Cardiovascular SurgeryClinical Variation Reduction in Propensity-matched Patients Treated for Malignant Pleural Effusion
2021, Annals of Thoracic Surgery